| Symbol | ACIU |
|---|---|
| Name | AC IMMUNE SA |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | EPFL INNOVATION PARK,BUILDING B, LAUSANNE, 1015, Switzerland |
| Telephone | +41 216939121 |
| Fax | — |
| — | |
| Website | https://www.acimmune.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Additional info from NASDAQ: |
Director Pfeifer Andrea 🔴 sold 10.0K shares of AC Immune SA (ACIU) at $3.14 Transaction Date: Apr 15, 2026 | Filing ID: 000005
Read moreNew Form 4/A - AC Immune SA <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001651625-26-000006 <b>Size:</b> 6 KB
Read more📋 ANDREA M.A PFEIFER (Officer) plans to sell 10K shares of AC IMMUNE SA (at $3.19 each, total $32K) Filed: Apr 15, 2026 | ID: 003516
Read moreAC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
Read moreNew Form 3 - AC Immune SA <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0000950103-26-005191 <b>Size:</b> 14 KB
Read moreNew Form 3 - AC Immune SA <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0000950103-26-004163 <b>Size:</b> 21 KB
Read moreNew Form 3 - AC Immune SA <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0000950103-26-004156 <b>Size:</b> 17 KB
Read moreNew Form 3 - AC Immune SA <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0000950103-26-004155 <b>Size:</b> 19 KB
Read moreNew Form 3 - AC Immune SA <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0000950103-26-004153 <b>Size:</b> 14 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07463196 | A Study Investigating the Safety, Absorption, Elimination, and the Effect on th… | Phase1 | Healthy Participants | Recruiting | 2026-01-28 | 2026-08-01 | ClinicalTrials.gov |
| NCT06891703 | [18F]ACI-15916 PET in α-synucleinopathies | Early_Phase1 | Parkinson's Disease (PD) | Recruiting | 2025-03-20 | 2026-03-01 | ClinicalTrials.gov |
| NCT06891716 | [18F]ACI-19626 PET in TDP-43 Proteinopathies | Early_Phase1 | Frontotemporal Dementia (FTD) | Recruiting | 2025-01-21 | 2026-11-01 | ClinicalTrials.gov |
| NCT06015841 | A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages o… | Phase2 | Parkinson Disease | Active_Not_Recruiting | 2023-07-24 | 2028-01-01 | ClinicalTrials.gov |
| NCT05462106 | A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down … | Phase1 | Amyloid Plaque | Recruiting | 2022-06-21 | 2026-06-01 | ClinicalTrials.gov |
| NCT04373616 | A Study of ACI-24 in Adults With Down Syndrome | Phase2 | Down Syndrome | Withdrawn | 2021-10-01 | 2024-10-01 | ClinicalTrials.gov |
| NCT05067192 | Optimization of Morphomer-based Alpha-synuclein PET Tracers | — | Parkinson Disease | Completed | 2021-07-15 | 2021-09-01 | ClinicalTrials.gov |
| NCT06445465 | Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Depos… | Early_Phase1 | Alpha-Synucleinopathy | Completed | 2020-12-24 | 2024-11-26 | ClinicalTrials.gov |
| NCT04445831 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted… | Phase1 | Alzheimer's Disease | Completed | 2019-07-31 | 2023-09-05 | ClinicalTrials.gov |
| NCT02738450 | Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down S… | Phase1 | Down Syndrome | Completed | 2016-03-01 | 2020-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ACI-19764 at dose B3 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose B2 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose B1 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A6 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A5 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A4 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A3 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A2 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A1 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| [18F]ACI-19626 | OTHER | Phase EARLY_PHASE1 | Frontotemporal Dementia (FTD) | RECRUITING | NCT06891716 |
| [18F]ACI-15916 | OTHER | Phase EARLY_PHASE1 | Parkinson's Disease (PD) | RECRUITING | NCT06891703 |
| [18F]MNI-1216 | DRUG | Phase EARLY_PHASE1 | Alpha-Synucleinopathy | COMPLETED | NCT06445465 |
| ACI-7104.056 at Dose C (optional) | BIOLOGICAL | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-7104.056 at Dose B (optional) | BIOLOGICAL | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-7104.056 at Dose A | BIOLOGICAL | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-24.060 at Dose D | BIOLOGICAL | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose C | BIOLOGICAL | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose B | BIOLOGICAL | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose A | BIOLOGICAL | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| JACI-35.054 | BIOLOGICAL | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT04445831 |
| ACI-35.030 | BIOLOGICAL | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT04445831 |
| ACI-24 | BIOLOGICAL | Phase PHASE2 | Down Syndrome | WITHDRAWN | NCT04373616 |
| Placebo | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-24 high dose | BIOLOGICAL | Phase PHASE1 | Down Syndrome | COMPLETED | NCT02738450 |
| ACI-24 low dose | BIOLOGICAL | Phase PHASE1 | Down Syndrome | COMPLETED | NCT02738450 |